News & Updates
Filter by Specialty:
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
Guideline-congruent screening for cervical cancer remains poor in women with systemic lupus erythematosus (SLE), according to a study.
Immunosuppressant exposure tied to guideline-congruent cervical cancer screening
24 Nov 2022
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
Use of glucagon-like peptide 1 (GLP-1) receptor agonists or sodium-glucose co-transporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, helps prevent severe exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D), a UK study has shown.
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
23 Nov 2022
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
Patients with moderate-to-severe systemic lupus erythematosus (SLE) appear to fare well with anifrolumab, with a recent study showing that the drug has an acceptable long-term safety profile and helps maintain reductions in disease activity and glucocorticoid usage.
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
22 Nov 2022
TB rates elevated after ART initiation in PLHIV
People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.
TB rates elevated after ART initiation in PLHIV
21 Nov 2022
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
21 Nov 2022
Biologics prevent infection-related hospitalization in IBD patients with comorbidity
Treatment with vedolizumab or ustekinumab leads to reduced rates of infection-related hospitalization compared with antitumour necrosis factor-α antagonists (anti-TNF) among adults with inflammatory bowel disease (IBD) initiating biologic therapy and with high comorbidity burden, reports a recent study.
Biologics prevent infection-related hospitalization in IBD patients with comorbidity
20 Nov 2022
High-flow oxygen does not reduce mortality in COVID-19 respiratory failure
The use of high-flow nasal cannula oxygen, as opposed to standard oxygen, in the first-line setting, did not reduce mortality rates in patients admitted to intensive care units (ICUs) for respiratory failure due to COVID-19, results of the SOHO-COVID trial showed.
High-flow oxygen does not reduce mortality in COVID-19 respiratory failure
20 Nov 2022
CRT vs SBRT: Which approach yields better outcomes in PDAC?
Multiagent chemotherapy (MAC) followed by conventionally fractionated radiotherapy (CRT) shows rates of margin-negative resection (R0) and pathologic complete response similar to those of MAC plus stereotactic body radiotherapy (SBRT) in patients with localized pancreatic ductal adenocarcinoma (PDAC), according to a study. However, MAC plus CRT is associated with less regional lymphatic disease.